Welcome to our dedicated page for NetraMark Holdings news (Ticker: AINMF), a resource for investors and traders seeking the latest updates and insights on NetraMark Holdings stock.
NetraMark Holdings Inc. reports developments tied to artificial intelligence for clinical trial optimization and precision medicine in the pharmaceutical industry. Its recurring updates center on the NetraAI platform, which is designed to analyze complex clinical datasets, identify model-derived patient subgroups, and support patient stratification, enrichment strategies, and trial-design decisions.
Company news commonly covers pharmaceutical and research collaborations, contracts to analyze clinical trial data, peer-reviewed work, conference presentations, and clinical leadership additions. Reported therapeutic areas include central nervous system disorders, depression, Alzheimer’s disease, oncology, and regulated botanical wellness, with emphasis on explainable analytics, biomarker-guided insights, and responder or placebo-sensitive patient populations.
NetraMark (OTCQB: AINMF / CSE: AIAI) reported a transformational quarter with commercial, regulatory, and scientific milestones. Key items: contract backlog rose to C$2.5M; the company reiterated its target of C$8–10M backlog by mid‑2026. NetraMark completed a FDA Critical Path Innovation Meeting (CPIM) on NetraAI, received guidance on enrichment methodology and Type I error control, and was advised to consider the FDA MIDD paired meeting pathway. The company had a Nature Portfolio (npj Digital Medicine) study accepted (Dec 8, 2025) validating NetraAI in a Phase II depression trial. Commercially, Worldwide Clinical Trials onboarding finished in mid‑October, enabling inclusion in Phase 2/3 bids, and a CAMH collaboration secured an Ontario Research Fund award.
NetraMark (OTCQB: AINMF) and the Centre for Addiction and Mental Health announced on December 16, 2025 that they received an Ontario Research Fund - Research Excellence award to deploy NetraAI in CAMH’s secure HPC environment.
The project will analyze genetic and epigenetic data from schizophrenia and major depressive disorder studies to identify explainable patient subpopulations, support precision treatment strategies, and refine NetraAI for pharmaceutical clinical trials. Installation is led by CAMH Research IT with on-site NetraMark support; analyses will use de-identified data under CAMH privacy and security standards. The collaboration also includes evaluation of an OHIP administrative “bonus dataset” for cost-effectiveness and health-system impact analyses.
NetraMark (OTCQB: AINMF) announced completion of a Critical Path Innovation Meeting (CPIM) with FDA on December 15, 2025.
FDA provided scientific feedback on NetraAI's explainable AI/ML enrichment approach, recommended considering the MIDD Paired Meeting Program for further regulatory dialogue, and discussed potential applications including targeted inclusion/exclusion criteria, pre-specified stratification in the SAP, and trial simulations to assess power and robustness.
The company emphasized the CPIM's non-binding nature and said the discussion clarified regulatory considerations and potential pathways to support Phase 2/3 trial design.
NetraMark (OTCQB: AINMF) announced it was awarded a new contract from a global biopharmaceutical company to support analytics for a pivotal Phase 3 clinical trial, executed under an existing master services agreement on Dec 11, 2025. The engagement expands NetraMark’s role into late‑stage decision support using NetraAI to identify explainable patient subpopulations (responders, non‑responders, placebo‑associated) and analyze treatment and placebo‑response patterns.
The analytics aim to strengthen interpretation of trial outcomes across result scenarios and support clinical, regulatory, and commercial planning, reinforcing repeat business and growing adoption of NetraAI in Phase 3 programs.
NetraMark (OTCQB: AINMF) announced acceptance of a peer‑reviewed paper, “Explainable AI‑Driven Precision Clinical Trial Enrichment,” in npj Digital Medicine on Dec 8, 2025. The study demonstrates the NetraAI platform using data from a National Institute of Mental Health Phase II ketamine trial in treatment‑resistant depression to identify interpretable Model Derived Subgroups (MDS) that could inform precision enrichment.
The paper highlights NetraAI’s use of explainable, mathematically grounded AI, dynamical‑systems modeling, long‑range‑memory feature learning, and LLM‑augmented explainability to improve clinical interpretability and trial decision‑making.
NetraMark (OTCQB: AINMF) announced four new contracts with a leading global pharmaceutical company, signed under an existing master services agreement, to apply its proprietary NetraAI platform to clinical data from four late-stage pivotal studies on November 18, 2025.
The engagements will perform multi-study analyses to identify explainable patient subpopulations driving treatment and placebo response and to quantify clinical and demographic drivers of trial variability. NetraAI is described as a mathematically-augmented, interpretable AI system intended to align with FDA expectations for explainable AI in clinical development.
NetraMark (OTCQB: AINMF) announced a new contract with a leading global biopharmaceutical company to apply its NetraAI platform to a Phase 3 clinical trial of a novel psychiatric medicine, dated November 3, 2025.
Under the agreement, NetraMark will deploy its proprietary AI methodology to analyze multi-dimensional clinical data and identify explainable patient subpopulations tied to treatment response, placebo response, and adverse events. The outputs are intended to support regulatory and market access planning and to inform future pivotal study design.
NetraAI uses a dynamical systems framework aimed at finding high-effect-size subgroups and translating them into clinically interpretable enrichment criteria for investigators, regulators, and clinicians.
NetraMark (OTCQB: AINMF) presented AI-driven analyses at ISCTM and ECNP on Oct 29, 2025 demonstrating NetraAI’s ability to identify responder subgroups and improve prediction in major depressive disorder trials.
Key readouts: ketamine responder Personas diverged from placebo by infusion 2 (separation 1.0) and ketamine responder cohesion rose from 25% to ~67%. In CAN-BIND escitalopram data NetraAI reduced clinical features to 8 key variables, isolated a highly predictive responder subgroup, and reported 91% accuracy for that subgroup using hypomethylation at three gene sites.
NetraMark Holdings (OTCQB: AINMF) has announced a strategic collaboration to advance glioblastoma (GBM) research using its NetraAI platform. The company has secured access to clinical and biomarker datasets from a leading U.S. academic medical center to develop therapeutic decision support tools for future GBM trials.
The collaboration will analyze longitudinal cerebrospinal fluid (CSF) proteomic datasets through six key objectives, including distinguishing GBM samples, differentiating tumor types, and studying disease recurrence patterns. The project aims to address the challenges in GBM treatment, where clinical trials face a 90% failure rate and patients have a median survival of just 15 months.
NetraMark Holdings (OTCQB: AINMF), an AI company specializing in clinical trial optimization, has appointed Dr. Jan Sedway as Senior Vice President of Clinical Science. Dr. Sedway brings over 20 years of leadership experience in clinical research and global operations, previously serving as Vice President of Clinical Development at Clario.
The appointment aligns with NetraMark's strategic expansion in the pharmaceutical industry, focusing on scaling its AI-powered solutions across psychiatry, oncology, and other therapeutic areas. Dr. Sedway's experience includes advancing digital biomarker solutions and driving operational excellence in global clinical trials, with previous leadership roles at Parexel and Syneos Health.